Join Abzena’s drug development experts at the upcoming Oligonucleotides for CNS Summit Europe in Amsterdam on April 21-23.  The summit delivers three days of highly technical, data-driven discussions addressing the challenges unique to CNS development, with insights into next-generation BBB delivery strategies beyond TfR1, advanced in vivo and iPSC models, novel chemistry and conjugation approaches, and translational strategies bridging preclinical data to clinical and regulatory success.

If you’re developing an antibody-oligo conjugate (AOC), schedule some time to speak with our experts at the event to learn how we can de-risk and streamline your program from IND through to the clinic!